Since CAL-51 cells harbor wild-type TP53, whereas the other two cell lines do not (Huovinen et al., 2011; Tentler et al., 2015), these results suggest that CMPD1 induces a robust prometaphase arrest in breast cancer cells through a p53-independent mechanism. Here, SOX9 is linked to breast cancer.